Literature DB >> 20070237

Antibiotic treatment duration and long-term outcomes of patients with early lyme disease from a lyme disease-hyperendemic area.

Todd J Kowalski1, Sujatha Tata, Wendy Berth, Michelle A Mathiason, William A Agger.   

Abstract

BACKGROUND: The length of antibiotic therapy and long-term outcomes in patients with early Lyme disease are incompletely described. We report the long-term clinical outcomes of patients with early localized and early disseminated Lyme disease based on the duration of antibiotic therapy prescribed.
METHODS: A retrospective cohort study and follow-up survey of patients diagnosed as having early localized and early disseminated Lyme disease from 1 January 2000 through 31 December 2004 was conducted in a Lyme disease-hyperendemic area.
RESULTS: Six hundred seven patients met the study inclusion criteria. Most patients (93%) were treated with doxycycline for treatment durations of 10 days, 11-15 days, or 16 days in 17%, 33%, and 47% of doxycycline-treated patients, respectively. Treatment failure criteria, defined before performing the study, were met in only 6 patients (1%). Although these 6 patients met a priori treatment failure criteria, 4 of these patients' clinical details suggested reinfection, 1 was treated with an inappropriate antibiotic, and 1 developed facial palsy early in therapy. Reinfection developed in 4% of patients. The 2-year treatment failure-free survival rates of patients treated with antibiotics for 10 days, 11-15 days, or 16 days were 99.0%, 98.9%, and 99.2%, respectively. Patients treated with antibiotics for 16 days had lower 36-item Short-Form Health Survey social functioning scores on the follow-up survey. No other differences were found in follow-up clinical status or 36-item Short-Form Health Survey scores by duration of antibiotic treatment.
CONCLUSIONS: Patients treated for 10 days with antibiotic therapy for early Lyme disease have long-term outcomes similar to those of patients treated with longer courses. Treatment failure after appropriately targeted short-course therapy, if it occurs, is exceedingly rare.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20070237     DOI: 10.1086/649920

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  25 in total

Review 1.  Chronic Lyme disease.

Authors:  Paul M Lantos
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

Review 2.  Lyme borreliosis.

Authors:  Allen C Steere; Franc Strle; Gary P Wormser; Linden T Hu; John A Branda; Joppe W R Hovius; Xin Li; Paul S Mead
Journal:  Nat Rev Dis Primers       Date:  2016-12-15       Impact factor: 52.329

3.  Rapid decline of OspC borreliacidal antibodies following treatment of patients with early Lyme disease.

Authors:  Dean A Jobe; Todd J Kowalski; Marissa Bloemke; S D Lovrich; Steven M Callister
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

4.  U.S. public's experience with ticks and tick-borne diseases: Results from national HealthStyles surveys.

Authors:  Sarah A Hook; Christina A Nelson; Paul S Mead
Journal:  Ticks Tick Borne Dis       Date:  2015-04-15       Impact factor: 3.744

5.  Detection of IFN-γ Secretion by T Cells Collected Before and After Successful Treatment of Early Lyme Disease.

Authors:  Steven M Callister; Dean A Jobe; Aleksandra Stuparic-Stancic; Misato Miyamasu; Jeff Boyle; Raymond J Dattwyler; Paul M Arnaboldi
Journal:  Clin Infect Dis       Date:  2016-03-01       Impact factor: 9.079

6.  Empiric antibiotic treatment of erythema migrans-like skin lesions as a function of geography: a clinical and cost effectiveness modeling study.

Authors:  Paul M Lantos; R Jory Brinkerhoff; Gary P Wormser; Robert Clemen
Journal:  Vector Borne Zoonotic Dis       Date:  2013-10-09       Impact factor: 2.133

7.  Development of a Multiantigen Panel for Improved Detection of Borrelia burgdorferi Infection in Early Lyme Disease.

Authors:  Lauren J Lahey; Michael W Panas; Rong Mao; Michelle Delanoy; John J Flanagan; Steven R Binder; Alison W Rebman; Jose G Montoya; Mark J Soloski; Allen C Steere; Raymond J Dattwyler; Paul M Arnaboldi; John N Aucott; William H Robinson
Journal:  J Clin Microbiol       Date:  2015-10-07       Impact factor: 5.948

Review 8.  Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review.

Authors:  Edgar Sanchez; Edouard Vannier; Gary P Wormser; Linden T Hu
Journal:  JAMA       Date:  2016-04-26       Impact factor: 56.272

9.  Identification of OppA2 linear epitopes as serodiagnostic markers for Lyme disease.

Authors:  Giacomo Signorino; Paul M Arnaboldi; Mary M Petzke; Raymond J Dattwyler
Journal:  Clin Vaccine Immunol       Date:  2014-03-12

10.  Management approaches for suspected and established Lyme disease used at the Lyme disease diagnostic center.

Authors:  Gary P Wormser; Donna McKenna; John Nowakowski
Journal:  Wien Klin Wochenschr       Date:  2016-01-14       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.